These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1216 related articles for article (PubMed ID: 34742052)
1. Molnupiravir in COVID-19: A systematic review of literature. Singh AK; Singh A; Singh R; Misra A Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052 [TBL] [Abstract][Full Text] [Related]
2. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Singh AK; Singh A; Singh R; Misra A Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686 [TBL] [Abstract][Full Text] [Related]
3. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C; N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868 [TBL] [Abstract][Full Text] [Related]
4. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. Caraco Y; Crofoot GE; Moncada PA; Galustyan AN; Musungaie DB; Payne B; Kovalchuk E; Gonzalez A; Brown ML; Williams-Diaz A; Gao W; Strizki JM; Grobler J; Du J; Assaid CA; Paschke A; Butterton JR; Johnson MG; De Anda C NEJM Evid; 2022 Feb; 1(2):EVIDoa2100043. PubMed ID: 38319179 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review. Mali KR; Eerike M; Raj GM; Bisoi D; Priyadarshini R; Ravi G; Chaliserry LF; Janti SS Ir J Med Sci; 2023 Aug; 192(4):1665-1678. PubMed ID: 36087236 [TBL] [Abstract][Full Text] [Related]
6. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis. Cheema HA; Abdul Rab S; Butt M; Jafar U; Shahid A; Rehman AU; Lee KY; Sahra S; Sah R J Microbiol Immunol Infect; 2024 Jun; 57(3):396-402. PubMed ID: 38555274 [TBL] [Abstract][Full Text] [Related]
7. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. Arribas JR; Bhagani S; Lobo SM; Khaertynova I; Mateu L; Fishchuk R; Park WY; Hussein K; Kim SW; Ghosn J; Brown ML; Zhang Y; Gao W; Assaid C; Grobler JA; Strizki J; Vesnesky M; Paschke A; Butterton JR; De Anda C NEJM Evid; 2022 Feb; 1(2):EVIDoa2100044. PubMed ID: 38319178 [TBL] [Abstract][Full Text] [Related]
8. Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis. Amani B; Amani B Immun Inflamm Dis; 2024 Apr; 12(4):e1262. PubMed ID: 38652021 [TBL] [Abstract][Full Text] [Related]
9. Molnupiravir: A new candidate for COVID-19 treatment. Pourkarim F; Pourtaghi-Anvarian S; Rezaee H Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008 [TBL] [Abstract][Full Text] [Related]
10. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. Khiali S; Khani E; B Rouy S; Entezari-Maleki T Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608 [TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study. Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies. Mesfin YM; Blais JE; Kibret KT; Tegegne TK; Cowling BJ; Wu P J Antimicrob Chemother; 2024 Sep; 79(9):2119-2131. PubMed ID: 38817046 [TBL] [Abstract][Full Text] [Related]
15. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Painter GR; Natchus MG; Cohen O; Holman W; Painter WP Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264 [TBL] [Abstract][Full Text] [Related]
17. Molnupiravir for the treatment of COVID-19. Santani BG; LeBlanc BW; Thakare RP Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of molnupiravir in the intended-use population: an observational cohort study. Abu Ahmad W; Arbel R; Wolff Sagy Y; Battat E; Sergienko R; Friger M; Yaron S; Serby D; Zucker R; Hammerman A; Duskin Bitan H; Peretz A; Lavie G; Netzer D Clin Microbiol Infect; 2024 Oct; 30(10):1305-1311. PubMed ID: 38942382 [TBL] [Abstract][Full Text] [Related]
19. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir. Waters MD; Warren S; Hughes C; Lewis P; Zhang F Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215 [TBL] [Abstract][Full Text] [Related]
20. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis. Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]